 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H40O3 |
| Molar mass | 376.581 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CP 55,940 is asynthetic cannabinoid which mimics the effects of naturally occurringTHC (one of the psychoactive compounds found incannabis). CP 55,940 was created byPfizer in 1974 but was never marketed. It is currently used as a research tool to study theendocannabinoid system.[1]
CP 55,940 is 45 times more potent than Δ9-THC, and fully antagonized byrimonabant (SR141716A).[2] It is considered a full agonist at both CB1 and CB2 receptors and hasKi values of 0.58 nM and 0.68 nM respectively, but is an antagonist atGPR55, the putative "CB3" receptor.[3] CP 55,940 binding has been detected in the cytosol of rat brain cerebral cortex.[4] It can upregulate5-HT2A receptors in mice.[5]
CP 55,940 induced cell death in NG 108-15 Mouse neuroblastoma x Rat glioma hybrid brain cancer (genetically engineered mouse x rat brain cancer) cells.[6][7]
CP 55,940 showed protective effects on rat brain mitochondria upon paraquat exposure.[8]
It also showed neuroprotective effects by reducing intracellular calcium release and reducing hippocampal cell death in cultured neurons subjected to high levels ofNMDA.[9]
